Abstract
Three modes of cancer therapy, surgery, radiation and chemotherapy, have been central to modern oncologic therapy. Molecular targeted cancer therapies have been introduced to target specific pathways, while minimizing side effects but have had limited success except in several notable cases. Here, we employ an activatable hydrophilic photosensitizer based on a near infrared (NIR) phthalocyanine dye, IR700, which is covalently conjugated to one of several humanized monoclonal antibodies (MAb) targeting cancer-specific cell-surface molecules. When exposed NIR light, the conjugate induces highly selective cell death in vivo, a process termed “photo-immunotherapy” (PIT) (1). (Fig. 1)
© 2014 Optical Society of America
PDF ArticleMore Like This
Hisataka Kobayashi
OM2D.2 Optical Molecular Probes, Imaging and Drug Delivery (OMP) 2015
Hisataka Kobayashi
ATu3A.4 CLEO: Applications and Technology (CLEO:A&T) 2017
Hisataka Kobayashi
AM1I.2 CLEO: Applications and Technology (CLEO:A&T) 2019